Unique ID issued by UMIN | UMIN000046197 |
---|---|
Receipt number | R000052724 |
Scientific Title | Evaluation of risk factors for post hepatectomy liver failure and efficiency of potal vein embolization for perihilar cholangiocarcinoma surgery |
Date of disclosure of the study information | 2021/11/26 |
Last modified on | 2024/07/07 13:30:48 |
Evaluation of risk factors for post hepatectomy liver failure and efficiency of potal vein embolization for perihilar cholangiocarcinoma surgery
Evaluation for PHLF and efficiency for PTPE
Evaluation of risk factors for post hepatectomy liver failure and efficiency of potal vein embolization for perihilar cholangiocarcinoma surgery
Evaluation for PHLF and efficiency for PTPE
Japan |
Perihilar Cholangiocarcinoma
Hepato-biliary-pancreatic surgery |
Malignancy
NO
Evaluate risk factors for post hepatectomy liver failure and find to prevent it.
Efficacy
Risk factor for liver failure
Observational
Not applicable |
Not applicable |
Male and Female
Perihilar cholangiocarcinoma patients who underwent hepatectomy in Hokkaido University Gastroenterological surgery II
1. Early period death
2. Lacking clinical data
3. Other
310
1st name | Takehiro |
Middle name | |
Last name | Noji |
Hokkaido University Hospital
Faculty of Medicine Gastroenterological surgery II
060-8638
Kita15 Nishi7 Kitaku Sapporo city Japan
0117067714
drnoji@med.hokudai.ac.jp
1st name | Takehiro |
Middle name | |
Last name | Noji |
Hokkaido University Faculty of Medicine
Gastroenterological surgery II
060-8638
Kita15 Nishi7 Kita-ku, Sapporo city, Hokkaido, japan
0117067714
drnoji@med.hokudai.ac.jp
Hokkaido University
self funding
Self funding
IRB Hokkaido University Hospital
Kita 14 Nishi 5, Kitaku, Sapporo city
011-706-1161
crjimu@huhp.hokudai.ac.jp
NO
2021 | Year | 11 | Month | 26 | Day |
Unpublished
365
The incidence of liver failure after hepatic lobectomy for hilar cholangiocarcinoma was 27.5%. Cases other than hepatic left caudate lobe resection were independent risk factors. Analysis of only the group of patients who underwent portal vein embolisation revealed that ICGKF <0.05, operative time >660 min and blood loss >1900 ml before portal vein embolisation were independent risk factors, and the operative mortality rate was 25% in cases requiring these three factors.
2024 | Year | 07 | Month | 07 | Day |
Delay expected |
Paper is not accepted
Completed
2021 | Year | 08 | Month | 20 | Day |
2021 | Year | 10 | Month | 15 | Day |
2021 | Year | 12 | Month | 01 | Day |
2022 | Year | 03 | Month | 31 | Day |
(1) Type and design of the study
Observational study using existing information
(2) Research questions
The following information will be obtained and used for the study subjects until 31 March 2022.
(1) Background information: age, sex, medical history, diagnosis, treatment history, performance status
2) Hematological examination results: hemoglobin, white blood cell count, white blood cell fraction and platelet count
3) Blood chemistry test results: total protein, albumin, Na, K, serum tumor marker (CEA/CA19-9)
4) CT, MRI, ultrasound and cholangiogram results
5) Results of histopathological examination (histological type, degree of progression, lymph node metastasis)
(6) Operative procedure, operative time, amount of blood loss
(7) Postoperative course (presence of complications)
(viii) Treatment administered during postoperative hospitalization and duration.
(ix) Date of discharge, cause of death.
2021 | Year | 11 | Month | 26 | Day |
2024 | Year | 07 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052724